Clinical Scorecard: Retrospective Analysis of a Rare Collision Tumor: Mantle Cell Lymphoma Coexisting with Rectal Adenocarcinoma and Molecular Profiling of Multiple Specimens

At a Glance

Key Highlights

• Rare occurrence of synchronous rectal adenocarcinoma and mantle cell lymphoma.
• Molecular profiling revealed shared TP53 mutations and distinct NOTCH2 alterations.
• Retrospective analysis of surgical specimens can uncover hidden malignancies.
• Patient treated with bendamustine, rituximab, and zanubrutinib, remaining in remission.

Guideline-Based Recommendations

Diagnosis

• Consider molecular profiling in cases of unexpected lymphadenopathy post-cancer treatment.

Management

• Utilize targeted therapies such as bendamustine and rituximab for mantle cell lymphoma.

Monitoring & Follow-up

• Regular follow-up imaging and clinical assessment for recurrence of lymphoma.

Risks

• Potential for misdiagnosis of lymphoma in the presence of predominant adenocarcinoma.

Patient & Prescribing Data

Older adults with colorectal cancer and incidental lymphoma.

Combination therapy with bendamustine and rituximab followed by maintenance therapy.

Clinical Best Practices

• Conduct thorough pathological reviews of surgical specimens for incidental findings.
• Implement molecular profiling for comprehensive understanding of tumor biology.

Related Resources & Content